Search Results - "DEL CAMPO, J. M"

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck by Seiwert, T.Y., Fayette, J., Cupissol, D., del Campo, J.M., Clement, P.M., Hitt, R., Degardin, M., Zhang, W., Blackman, A., Ehrnrooth, E., Cohen, E.E.W.

“…Afatinib is an oral, irreversible ErbB family blocker that has shown activity in epidermal growth factor receptor (EGFR)-mutated lung cancer. We hypothesized…”
Get full text

Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck by del Campo, J M, Hitt, R, Sebastian, P, Carracedo, C, Lokanatha, D, Bourhis, J, Temam, S, Cupissol, D, De Raucourt, D, Maroudias, N, Nutting, C M, Compton, N, Midwinter, D, Downie, L, Biswas-Baldwin, N, El-Hariry, I, Harrington, K J

“…Background: Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER-2) tyrosine kinases. This study investigated the…”
Get full text

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer by Del Campo, J. M., Roszak, A., Bidzinski, M., Ciuleanu, T. E., Hogberg, T., Wojtukiewicz, M. Z., Poveda, A., Boman, K., Westermann, A. M., Lebedinsky, C.

“…Background: This randomized, open-label, phase II clinical trial evaluated the optimal regimen of trabectedin administered every 3 weeks in patients with…”
Get full text

Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer by Prat, A., Parera, M., Peralta, S., Perez-Benavente, M. A., Garcia, A., Gil-Moreno, A., Martinez-Palones, J. M., Roxana, I., Baselga, J., Del Campo, J. M.

“…Background: The amount of residual disease after surgery is considered the most important factor influencing the survival of patients with advanced epithelial…”
Get full text

Nonepileptic visual hallucinations in Lafora disease by ANDRADE, D. M, DEL CAMPO, J. M, MORO, E, MINASSIAN, B. A, WENNBERG, R. A

Get full text

Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels by Prat, A., Parera, M., Adamo, B., Peralta, S., Perez-Benavente, M. A., Garcia, A., Gil-Moreno, A., Martinez-Palones, J. M., Baselga, J., del Campo, J. M.

“…Background: Our group evaluated the risk of recurrence for optimally treated advanced epithelial ovarian cancer (adEOC) in patients with a low-level rising…”
Get full text

Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second–third line erlotinib by Cedrés, Susana, Prat, Aleix, Martínez, Pablo, Pallisa, Esther, Sala, Gemma, Andreu, Jordi, del Campo, J.M, Quispe, Isela, Baselga, José, Felip, Enriqueta

“…Summary Background Inhibition of the EGFR pathway is a useful strategy in the treatment of patients with advanced NSCLC. The aim of this study is to assess…”
Get full text

First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin by Kristensen, G B, Vergote, I, Stuart, G, Del Campo, J M, Kaern, J, Lopez, A B, Eisenhauer, E, Aavall-Lundquist, E, Ridderheim, M, Havsteen, H, Mirza, M R, Scheistroen, M, Vrdoljak, E

“…The objective of this study was to compare the safety and efficacy of carboplatin plus epirubicin and paclitaxel (TEC) to carboplatin and paclitaxel (TC), in…”
Get more information

Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study by Oaknin, Ana, Roda, Desamparado, González-Martín, Antonio, Chiva, Luis, García-Donas, Jesús, de Juan, Ana, Redondo, Andrés, Martínez, Sergio, García, Yolanda, Catot, Sílvia, Ponce, Jordi, Del Campo, J M, Cervantes, Andrés, Poveda, Andrés

“…The objective of the study was to assess the feasibility, toxicity, and reasons for early discontinuation of a modified outpatient intraperitoneal/intravenous…”
Get more information

Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer by Vergote, I, du Bois, A, Floquet, A, Rau, J, Kim, J.-W, del Campo, J.M, Friedlander, M, Pignata, S, Fujiwara, K, Colombo, N, Mirza, M.R, Monk, B.J, Tsibulak, I, Calvert, P.M, Herzog, T.J, Hanker, L.C, Meunier, J, Lee, J.-Y, Bologna, A, Carrasco-Alfonso, M.J, Harter, P

“…AbstractObjectiveThe AGO-OVAR16 study was designed to test the efficacy, safety, and tolerability of pazopanib maintenance after first-line chemotherapy in…”
Get full text

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer by Cohen, E.E.W., Licitra, L.F., Burtness, B., Fayette, J., Gauler, T., Clement, P.M., Grau, J.J., del Campo, J.M., Mailliez, A., Haddad, R.I., Vermorken, J.B., Tahara, M., Guigay, J., Geoffrois, L., Merlano, M.C., Dupuis, N., Krämer, N., Cong, X.J., Gibson, N., Solca, F., Ehrnrooth, E., Machiels, J.-P.H.

“…In the phase III LUX-Head & Neck 1 (LUX-H&N1) trial, second-line afatinib significantly improved progression-free survival (PFS) versus methotrexate in…”
Get full text

Predictive value of P53, Bcl-2, and BAX in advanced head and neck carcinoma by CASADO, Susana, FORTEZA, Jeronimo, DOMINGUEZ, Severina, ABAD, M. Teresa, PEREZ, Isabel, INTXAURBE, Iratxe, DEL CAMPO, J. M, LOPEZ, Rafael

“…Because the apoptotic process appears to be involved in the response-to-treatment of chemotherapy and radiotherapy, we investigated the prognostic value of the…”
Get full text

Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer by Poveda, A., del Campo, J.M., Ray-Coquard, I., Alexandre, J., Provansal, M., Guerra Alía, E.M., Casado, A., Gonzalez-Martin, A., Fernández, C., Rodriguez, I., Soto, A., Kahatt, C., Fernández Teruel, C., Galmarini, C.M., Pérez de la Haza, A., Bohan, P., Berton-Rigaud, D.

“…PM01183 is a new compound that blocks active transcription, produces DNA breaks and apoptosis, and affects the inflammatory microenvironment. PM01183 showed…”
Get full text

Analysis of the phenomenon of material expansiveness in tunnels built in anhydrite. Outcomes and experiences by Del Campo, J M, Guerra, J C, Fernandez-Ordonez, D

“…The serious geotechnical problems arising in many tunnels bored in material giving rise to stability problems as a result of being expansive, makes the water…”
Get full text

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up by Colombo, N., Creutzberg, C., Amant, F., Bosse, T., González-Martín, A., Ledermann, J., Marth, C., Nout, R., Querleu, D., Mirza, M.R., Sessa, C., Abal, M., Altundag, O., Amant, F., van Leeuwenhoek, Antoni, Banerjee, S., Bosse, T., Casado, A., de Agustín, L.C., Cibula, D., Colombo, N., Creutzberg, C., del Campo, J.-M., Emons, G., Goffin, F., González-Martín, A., Greggi, S., Haie-Meder, C., Katsaros, D., Kesic, V., Kurzeder, C., Lax, S., Lécuru, F., Ledermann, J., Levy, T., Lorusso, D., Mäenpää, J., Marth, C., Matias-Guiu, X., Morice, P., Nijman, H.W., Nout, R., Powell, M., Querleu, D., Mirza, M.R., Reed, N., Rodolakis, A., Salvesen, H., Sehouli, J., Sessa, C., Taylor, A., Westermann, A., Zeimet, A.G.

“…The first joint European Society for Medical Oncology (ESMO), European SocieTy for Radiotherapy & Oncology (ESTRO) and European Society of Gynaecological…”
Get full text

B88 exchange functional recovering the local spin density linear response by Campo, J. M. del

“…Following the strategy described in the landmark paper generalized gradient approximation (GGA) made simple (Perdew et al. in Phys Rev Lett 77(18):3865, 1996…”
Get full text

Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial by Clement, P.M., Gauler, T., Machiels, J.P., Haddad, R.I., Fayette, J., Licitra, L.F., Tahara, M., Cohen, E.E.W., Cupissol, D., Grau, J.J., Guigay, J., Caponigro, F., de Castro, G., de Souza Viana, L., Keilholz, U., del Campo, J.M., Cong, X.J., Ehrnrooth, E., Vermorken, J.B.

“…In the phase III LUX-Head & Neck 1 (LHN1) trial, afatinib significantly improved progression-free survival (PFS) versus methotrexate in recurrent and/or…”
Get full text

Impact of Offshore Wind Farms on Marine Ecosystems, Pelagic Species and Fishing by Negro, Vicente, del Campo, J. M., Frades, J. Luengo, Antón, Mario Martín, Esteban, M. Dolores, López-Gutiérrez, José-Santos, Soukissian, Takvor

“…Negro, V.; Del Campo, J.M.; Luengo Frades, J.; Martín Antón, M.; Esteban, M.D.; López – Gutiérrez, J.S., and Soukissian, T., In: Malvárez, G. and Navas, F…”
Get full text

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m(2) 24 h or 1.3 mg/m(2) 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer by M Del Campo, J, Roszak, A, Bidzinski, M, Ciuleanu, T E, Högberg, Thomas, Wojtukiewicz, M Z, Poveda, A, Boman, K, Westermann, A M, Lebedinsky, C

“…Patients and methods: Patients previously treated with less than two or two previous chemotherapy lines were randomized to receive trabectedin 1.5 mg/m(2) 24 h…”
Get full text

SEOM guideline in ovarian cancer 2014 by Gonzalez-Martín, A., Bover, I., Del Campo, J. M., Redondo, A., Vidal, L.

“…Ovarian cancer is the leading cause of death due to gynecological cancer and the 5th cause of death for cancer in women in Europe. Optimal management of…”
Get full text